Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003...
Saved in:
相似書籍
-
Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
由: Tanin Intragumtornchai, et al.
出版: (2018) -
Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability
由: Tanin Intragumtornchai, et al.
出版: (2018) -
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry
由: Kitsada Wudhikarn, et al.
出版: (2018) -
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry
由: Kitsada Wudhikarn, et al.
出版: (2018) -
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
由: Kitsada Wudhikarn, et al.
出版: (2020)